What question did this study set out to answer?

This research aims to create and evaluate 3D bioprinted models of colorectal cancer to understand their drug sensitivity and effectiveness.

August 13, 2026APL BioengineeringOpen Access

Construction of 3D bioprinted colorectal cancer models and evaluation of their efficacy and drug sensitivity

View Full Paper

Ask AI

Bookmark

Randomized trial establishes 3D bioprinted colorectal cancer models to evaluate drug efficacy, indicating promise for precision medicine.

This research aims to create and evaluate 3D bioprinted models of colorectal cancer to understand their drug sensitivity and effectiveness.
Utilized 3D bioprinting technology to create extracellular matrix models using GelMA and laminin/entactin complex.
Assessed biocompatibility and proliferation with calcein-AM and CellTiter-Glo assays on SW620 and primary CRC cells.
Conducted transcriptome sequencing and drug tests on the constructed 3D bioprinted CRC organoid models.
The 3D bioprinted organoid model showed high biocompatibility and enhanced tumor cell proliferation and invasion.
LE2 was found to activate the ErbB/Wnt signaling pathway, promoting cell interactions rather than depending on mechanical properties.
There was a significant correlation between clinical treatment outcomes for CRC patients and the drug test results from the 3D models.

A 2026 study studied this question.

View Full Paper

Ask AI

Bookmark